Concepedia

Author

Vladimír Maisnar

Charles UniversityORCID

Also Known As

Maisnar, V., Maisnar, Vladimir, V Maisnar, V. MAISNAR, V. Maisnar, Vladimir Maisnar, Vladimír MAISNAR, Vladimír Maisnar

250

Publications

4.3K

Citations

23

H-Index

51

Concepts

All Affiliations

Charles UniversityUniversity Hospital BrnoUniversity Hospital Hradec KrálovéUniversity Hospital OlomoucUniversity Hospital Ostrava
VM

About

Vladimír Maisnar is an author at Charles University specializing in hematology, immunology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

19

1.8K

2

Health Sciences

6

6

171

3

Public Health

1

1

11

4

Allergy

1

1

10

5

Blood Transplantation

1

1

25

Vladimír Maisnar

×

44

Publications

3.7K

Citations

22

H-Index

YearCitations

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos,

New England Journal of Medicine

2014

1.3K

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar,

The Lancet

2019

620

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç,

The Lancet Haematology

2020

377

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold,

The Lancet

2018

231

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Hervé Avet‐Loiseau, Rafaël Fonseca, David S. Siegel,

Blood

2016

120

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Roman Hájek, Tamás Masszi, Maria Teresa Petrucci,

Leukemia

2016

118

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, Sara Bringhen, Massimo Offidani,

Blood

2016

94

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Ajai Chari, Paula Rodríguez‐Otero, Helen O. McCarthy,

British Journal of Haematology

2020

60

Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma

Xavier Leleu, Tamás Masszi, Nizar J. Bahlis,

American Journal of Hematology

2018

49

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Tomáš Jelı́nek, Tereza Ševčíková, David Žihala,

Leukemia

2021

49

Page 1